Replay available

Bajaj Healthcare (NSE:BAJAJHCARE) Q1 2027 Earnings Call

Bajaj Healthcare (NSE:BAJAJHCARE) Q1 2027 earnings call, held 2026-07-21. Watch the replay and read the transcript on 6ix.

Tue, July 21, 2026 at 9:26 AMendedReplay
Bajaj Healthcare (NSE:BAJAJHCARE) Q1 2027 Earnings Call
Company
Bajaj Healthcare Ltd (NSE:BAJAJHCARE)
Period
Q1 2027 earnings call
Date
Tue, Jul 21, 2026, 9:26 AM ET
Replay
Watch the replay on this page · 40 min

On 6ix: 6ix.com/event/bajaj-healthcare-limited-bajajhcare-q1-2027-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, good day, and welcome to Bajaj Healthcare q one FY twenty seven earnings conference call. As a reminder, all participant lines will be in the listen only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing 0 on your touch tone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Bajaj from MUFC Insight. Thank you and over to you ma'am. Thank you, Good afternoon everyone. On behalf of Bajaj Healthcare Limited, I extend a warm welcome to all the participants on the Q one FY twenty seven financial results discussion call. Today on the call, we have Mr., Managing Director Mr. Rohan Parekh, Chief Financial Officer.

0:50 Before we begin the call, I would like to give a short disclaimer. This call contains some of the forward looking statements, which are completely based on our expectations, beliefs and opinions as of today. These statements are not a guarantee of our future performance and involve unforeseen risks and uncertainties. With this, I would like to hand over the call to Mr. Anil Jain for his opening remarks. Over to you sir and good evening. Thank you. A very good afternoon to everyone. On behalf of Bajaj Healthcare team, it's a privilege to welcome all of you to our earnings conference call. Strategically, we see our business under two verticals. The first one is our API business, our foundation business, where we manufacture various API intermediate.

1:39 We are also expanding into high value science based API like peptide and ongo, where we have already developed four modules with two scales to pilot level and six more under development. To commercialize this pipeline, we are getting up a dedicated peptide manufacturing facility with a installed capacity of approximate two fifty kgs per annum, targeted for commissioning by Q4 twenty twenty seven. Another key focus area is oncology API, where we are building a dedicated manufacturing facility, which will commercialize and the target date by Q4 twenty twenty eight.

2:25 Next comes our formation business, where we are constantly shifting our mix towards high margin branded and specialized products. We are pleased to share that Bajaj Healthcare has become the first company in India to secure FCC recommendation for manufacturing and marketing of cinevomib tablets and we have also successfully completed the b that is by full study of fluorescence tablets and are processing towards the regulatory approval procedures. These are meaningful, first mover regulatory milestones in CNS therapy space. On oncology side, our dedicated platform, Bajaj OncoCare was launched in 2024, already has a presence across 23 states and three Indian diets with 15 plus brands and we are the first in India to launch Pozaconazole three hundred milligram tablet, a differentiated formulation aimed to improve treatment agility and patient experience.

3:33 We also continue to strengthen our position as a trusted supplier to institute and government healthcare program, including Indian Airways, Defense, ESIC and Genocele. This requires exclusive licensing rights from the innovator for manufacturing and commercializing of magnesium as Qionics capsule, which is sold globally as a a specialty nutraceutical ingredient, which we believe represents a new growth avenue. We are also supplying this nutraceutical magnesium and ceramides to our patient holder in US. We expand our DSIR approval R and D center at Kabi with a team of experienced scientists, a new large r and d facility spanning over 10,000 square feet expected to operational by August 2026.

4:29 We will house more than 100 research under one roof. Our R and D spending as a percentage of sales has scaled meaningfully from 0.4% in 2024 to 2.2 in 2026. We strengthened our formation business through the acquisition of Generalized Pharmaceuticals, manufacturing facility in Nafin, which is currently under the NCLG approval process. The facility enhanced our capacity across solid dosage form and provides a strategic platform for expanding our formulation and oncology businesses. Following the receipt of the request approval and licensing, commercial production is expected to commence by second half of twenty twenty seven.

5:19 With that, let me hand over a call to Mr. Rohan Palik, our CFO, who will be walking through the financial performance of the quarter in detail. Rohan, over to you. Thank you, Anjali, and good afternoon to everyone. Let me take you through our financial performance, starting with the quarter and then provide some context on the historical trends. In quarter one FY twenty twenty seven, we reported a revenue of INR165.6 crores compared to INR148.8 crores in quarter one FY 'twenty six and INR153.1 crores in quarter four FY 'twenty six, which is a growth of 11.3% year on year and 8.2% sequentially.

6:05 Gross profit for the quarter stood at INR 80.4 crores, up by 16.2% year on year compared to INR69.1 crores in quarter one FY 'twenty six. Gross margin percentage expanded by two ten basis points to 48.3%. EBITDA for the quarter is at about INR29.6 crore, 17.8%, an improvement of 70 basis points year on year as compared to 17.1% in quarter one last year and 110 basis points over sequentially over quarter four of last year. Profit after tax from continuing operations stood at about INR 13.9 crores, up by 14.1% year on year from 12.2 crores in quarter one last year and broadly remaining stable versus 13.8 crores in quarter four, translating into a flat margin from continuing operations of 8.4%.

7:02 Domestic KPI was a key growth driver during the quarter, growing to 27% year on year, which is about INR92.3 crores, while export and commission business contributed to INR50.1 crores and INR23.3 crores, respectively. We expect the revenue mix to gradually normalize towards historical level as export improves and geopolitical conditions ease over the course of the year. As of 03/31/2026, our net worth stood at INR $5.33 crores, up from INR $4.56 crores last year. And our debt to debt equity equity improved further to 0.45 as compared to 0.48 in FY 'twenty five and one point one nine in FY 'twenty four.

7:48 It is a meaningful deleveraging from over last three years. On cash flows, net cash from operating activities for FY 'twenty six stood at about INR 58.1 crores, we ended the year with cash and cash requirements of INR 37.2 crores, up from INR 2.6 crores at the start of the year. Overall, we remain focused on sustaining our margin profile as we scale, continue to delever the balance sheet and improve our capital allocation, which will define our growth over coming few years. With that, we will now open the floor for questions. Thank you once again for joining us on this first earning call with Bajaj Healthcare. Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on your touch tone telephone.

8:37 If you wish to remove yourself from the question queue, you may press star and 2. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of from Ambit. Please proceed. Hi. Thank you for taking my question. So my first question is, can you please provide some indication as to how the API prices have been this quarter and how you expect them to be through the rest of the year? The API price has been more or less stable during this last quarter as compared to last quarter.

9:30 And it all depend upon the geopolitical situation, how it moves ahead. Then only we can add some... Something what we call everything depend on the oil and price. So right now, this quarter was fair enough with the stable API price. Right. So then the growth in the domestic API segment primarily came from volume growth and not from pricing. No. Okay. And so in your opening statement, you were mentioning details of some facilities, And you mentioned one of them which are... Which is to commercialize... The target commercialization for which is q four f y twenty eight. Which one is that? I I kinda missed that in your opening statement. That is the oncology API unit.

10:24 Okay. Oncology API And could you give any revenue and profitability guidance for FY twenty seven? So we can... The growth rate is around 10 to 15% for the next... This quarter... This year, 2027. Okay. And this is revenue growth you're talking? Revenue growth. Revenue revenue growth. Okay. And can you expect a similar growth rate for the profit? Yeah. Okay. Okay. Sure. Thanks for answering my questions. Thank you.

11:12 Thank you. The next question is from the line of Yogesh from High Farm Securities. Please proceed. Yeah. Hi. Thank you for the opportunity. I hope I'm audible. Yes. You are audible. Yeah. First question, sir, on the peptide synthesis part, I wanted to understand which are the peptide molecules that you're working on, and when it is likely to get commercialized from your end? So we are working on almost, like, six to seven molecules. I can give you the name one one of the one of the peptide that is tumor type. Rest are little confidential, so we cannot share right now over this conference call. Our plant is going going to commercialize in quarter four of this year.

12:02 So the first production will be hemagglutide production. Understood. And SEMA would be for India market or how it would be? Right right now, we are working for the India market, but the plant which is designed is for the global market. Okay. Understood. And I mean, on the Onco API part, if you could help us understand, I mean, what kind of plan do you have? When is the commercialization or I mean, commercialization likely to start? As I mentioned that this plan will be ready in quarter four of twenty twenty eight. Okay. Understood understood, sir. And sir, if you could just help me understand what is Bajaj OncoCare as well, this is the first time I'm attending your con call and not aware about OncoCare. Bajaj OncoCare is a division of Bajaj Healthcare, where we market our own brands of to the oncology patients.

13:03 It goes directly to to the... It's like a b to c business with our own 15 brands, working in 23 states and three union territories. Okay, understood. And sir, if you could help me understand what kind of a capital allocation policy are you looking at over the next two to three years? Whether the CapEx cycle for the company is completed or are we likely to see CapEx continue for the company? So the CapEx will be every year, we are we are allocating around 40 to 50 crores for next year. Every year, it will be like 40 to 50 crores capital expenditure. Okay. And any kind of acquisition that you are looking for?

13:48 Right now, nothing. We already acquired this Zenix RX, which is an NCLT. First, we will commercialize that plan, then we see how we move forward. Okay. And given that you are expecting commercialization of, let's say, peptide brand, the oncology as well. So are you expecting margin going forward to improve from the current mid to high teens level that you're seeing? Yeah. Yeah. There will be. But we are seeing a mix for... There is a lot of mix for changes from a high win... High volume to low volume products we are going. That's why we see oncology. There will be some improvement in the margin. Okay. Okay. Thank you, sir. I'll get back in the queue. Thank you.

14:39 Thank you. The next question is from the line of from Limited. Please proceed. Hello. Can you hear me? Yeah. I can hear you. Okay. Congratulations for the decent quarter. I have two questions. So firstly, basically, I am aware that your receivable days were higher because of the OPM business and the institutional state business, but you are working on reducing it. So what is the current receivable date, and is there scope for further reduction? Yeah. Hi, Sanjay. Rohan here. I'll take this transfer. So there is an improvement in the receivable date as compared to last financial year.

15:25 We have come down from one forty five days to one thirty one days as of quarter one of this year. We continue to work with our customers to improve this much further, but we anticipate it to be around one hundred and ten to one twenty days going forward. Okay. Okay. And my next question is, basically, any progress on the CDMO front on behalf of The UK and EU clients that you were working on? Like, we have already filed a DMS in UK and Europe. And we have already got six PP approval recently. Opioid in last six to eight months.

16:11 So these six molecules will be commercialized. It will take at least one year. Because once we get approved from the authority, that is European or the the agencies, it takes another one to one and a half years to get an customer approval. This is a timeline that is required to... For them, for the customer to make a bet, keep on stability, and then come to flight. So the first batch of revenue can be expected in FY '29. That's what you're saying? '28. '28. And twenty eight n. Twenty eight n. And what would the quantum be? Quantum, we are just analyzing it. How the things are moving, how... What time... What... That time, what... How much revenue we can get, what is the price. It depends after one one one and a half years, what will be the price of the molecules. It all depend upon that. But the volume is good, then we can tell you.

17:09 Okay. Okay. And going forward there, for FY '27, you have guided 10 to 15% top line growth. Can the similar rate of growth be expected for FY '28 as well? Yes. Yes. Okay. And my last question is you were supposed to sell off three loss making plants in Sarapur. So what's the progress? Have you sold off all the three... All three of them? No. Two are already left. Left, all we have sold. So you have sold one and two are left. Right? Correct. And how much sale proceeds can be expected from those two? We're expecting around I'm sorry. From the remaining two units, we're still on a look out from a buyer. So once we are able to negotiate Okay.

18:03 Okay. I see. Okay. Thank you. Those were the questions from my end. Thank you. Thank you very much. Thank you. The next question is from the line of Nirali Shah from Ashika Investment Management. Please proceed. Hi. Thank you for the opportunity. Firstly, congratulations on becoming the first company in that to receive the SEC recommendation. Beyond the regulation milestone, could you help us understand the commercial opportunity where we should focus primarily considering this opportunity? So we have got this tech committee approval.

18:49 We are still awaiting the approval from their BCGI, that is NOC and the state license. After that, the product will become a site. We have already hired with the eight companies in India, who will be marketing this product. We'll be a CDO partner for them. Okay. And if you can quantify this opportunity? So the launching quantity and put over this year, it will around 10 to 12 rupees. 27? Yeah. 27. Okay. And my second question is on the peptide facility.

19:37 Could you help understand what milestones remain between the commissioning and the commercial revenues inflow? So the commercialization will be last quarter of twenty twenty seven, as I mentioned, and the revenue will be in 2028. So we can expect customer qualifications and validation to extend in 2028 or everything of that will be done before that? No. No. No. But without without the plan commercialization, nothing happened. Only sample approval will be done, but actual production product has to go to the customer. Yes. So so probably commercial revenues would start coming in in the second half of twenty eight. Is that fair understanding? Yeah. Yeah. Yeah.

20:28 Okay. Thank you. Thank you. The next question is from the line of from. Please proceed. Yes. Thank you for hosting the first ever earnings call, Rohan and Anilji. Hopefully, this becomes a permanent part of Bajaj Healthcare's governance. In India, we have seen companies begin investor calls during good period only to discontinue them when business conditions become more challenging. To my mind, consistency across the cycle builds far more trust and consistency only during good times. That said, I have three questions for you, Ron.

21:16 Since... So first is since joining, what are the two or three biggest changes you have made to the finance function that investors may not immediately see in the reported numbers? Thank you, Bajaj. I have questions to answer on earnings call. The top three would be, one is to relook at our debt cost, the finance cost and realign. The second is to look at our working capital allocation. And the third is to work on the discontinued units. One more point I would like to pick is cost optimization for operating costs across the plan.

22:10 Sure. Sure. No. That's helpful. And second is, you know, following last year's write off, what has changed in the way you recognize revenue and manage the conversion of EBITDA into operating cash flow, please? Just to give you feedback on last year's write off, it was a one off and one time write off that we took From a sense from a revenue standpoint, the revenue is recognized once we dispatch. Once we dispatch. Just to give a feedback on the last year's write off, there was no cash flow. There was a write back of an income.

23:02 I hope I have answered your question. Yeah. Yeah. No. So so going forward, can we expect over the next, let's say, five years, the conversion of EBITDA into operating cash flow to be materially better than what we have done in the last five years? That that precisely what I'm asking. Yes, We can expect that. Okay. Okay. Sure. That's helpful. That's very encouraging. And finally, you know, if you compare Bajaj Healthcare, let's say, three years from now, which balance sheet metric do you want investors to judge the performance of the group on? Any one metric, three years from now, not immediately, not not about next quarter or or even this year, let's say, three years out. So three years down the line, return on equity and return on assets is what I would look at.

23:56 Sure. Sure. That's helpful. Thank you so much. Thank you. Thank you. The next question is from the line of from B portfolio. Please proceed. Hello. Thank you for this opportunity, sir. Sir, I want to know how much revenue do you expect from the twenty two fifty k g peptide, and will the margin be higher than the current 17%, sir? Again, this peptide is all open once we start this commercialization. And that two fifty metric ton will not be starting one day. It's a... It it it is it is built to give not only one API, but the API which will be coming in the next four years.

24:43 So we have designed a plan that that will cover and that will have a capacity up to two to three years. Okay. You are slowly ramping to the capacity and utilization over the years. Hello? Hello? You will slowly ramp up the capacity and utilization over the years, over two, three years, over next next two, three years. Yes. Sir, I want to know this, in peak demand or in peak utilization, how much you are expecting? The peak demand you are expecting from this plan? Once once we are to a peak and full utilization plan, we can expect anything around 200 to 200 to 300 crores of revenue.

25:32 And the margin would be sir, around 20% we can expect? More than 18 to 20%. Yeah. Okay. Thank you, sir. It's a month. Yes, sir. Okay. Thank you, sir. Thank you. The next question is from the line of from Counter Cyclic Investment. Please proceed. Sir, thank you for the opportunity. Sir, I wanted to understand, sir, what what is the backward integration level for our API business currently? So right now, we are working on a molecule, like, eight to 10 molecules that we are going to a backward integration. So this will help us to increase a little of margins in the product.

26:21 And also, the dependency on China will reduce. Right. So so I was reading your FY twenty minutes annual report, and in that, you mentioned that for vitamin c, we are, like, one of... We signed some MOU with ICT for, like, the production and, like, doing very backward integrated into this product. So if you could help us understand how many of our... So you mentioned eight to 10 products. So what percentage of our revenue would these products be, and what kind of margin improvement can we expect in your next one or two years from this backward integration that we are planning on doing? But then what we plan on it, MOU with the ICT, pseudo chemical technology, is totally backward integration of vitamin c.

27:10 This is a long long way to go because this is a fermentation product and India doesn't have... And no one is manufacturing in India from these groups. So this will be a patented technology that will be manufacturing vitamin c from the basic raw material. So we expect this to complete in 2029. Okay. I'm sure what... Mhmm. Yeah. So so what percentage of our revenue comes from vitamin c currently? If you would have the one. Right?

27:58 Anything between eight to 9%. Okay. Got it. And, sir, the other eight to 10 products where we are implementing backward integration measures, what percentage of our revenue would come from that? And what is the margin improvement can be? You can put together around 20 to 25% will come from that eight to 10 products, and there will be a marginal increase from one to 2%. Got it. Sir, now coming out to the API processing segment, sir, we were planning to sell some of the derivatives from that for whatever or coffee feed and the opium gum, whatever. So so what is the status of those products currently?

28:45 No. Opium gum, we are doing for the government of India. So we are, like, a... We are processing for them. So we are not selling any opiate. No. So sorry, sir. I think my question is okay. So do we... There were, like, two or three molecules or derivatives of these products that we could sell out to, like, either int... Intermediates to, I think, some foreign companies or, you know, pharma companies. So I was asking on that. Yes. We are still working on that market. The product is still in the r and d. The two two molecules from the OPA. And, sir, are there any discussions with the government for increasing this the the the business opportunity in terms of what the parties with the government?

29:37 Yeah. Yeah. We are still working on it. We have we have put our detail brief note to them, and they are still thinking because they have a lot of capital... A lot of store, what do call it, raw material line with them. Hopefully, we should get something. Got it. It. Now just just a final question from my end. Sir, on the working capital intensity, I think pre COVID, our business used to be very lean, and that is balloonizing the inventory. Although, recently, because I understand that because of the government contract, but our inventory inventory holding has also increased. So why... What has led to this increase, and what are we doing to, like, reduce it going forward?

30:26 Yeah. Hi. This is over here. So the inventory has increased as part of our internal policies because in quarter four, we saw this war situation developing, and we chose to order in few amount of inventories to ensure that we have our production going on for next couple of quarters. So going forward, we expect this to get better and not on the same line as quarter four or quarter one of this year. No, sir. I was so I was asking about your FY twenty one and FY twenty six. If I compare the inventory holding period of our revenue, it has ballooned, like, on similar revenue levels, it has almost doubled the inventory number. So why is that?

31:15 Question would be more on that. Because of the product mix in FY 'twenty one or I would say before COVID, we had a few less than 10 products, which were for the company, which was the product basket. And now we have deleveraged from that products to having many more products in the inventory. Okay. Got it. And so for FY '27 and '28, what kind of margin profile can you expect to maintain on a EBITDA level? 18 to 20%. 18 to 20%. Okay. So that is all mine. Thank you so much, and all the best. Thank you.

32:01 Thank you. The next question is from the line of Pat from financial asset manager. Please proceed. So good evening, everybody, and thank you for the opportunity. So going forward, where do you see the biggest growth opportunity? Domestic API, export API, formulation, specialty products. How do you expect the revenue mix to to evolve over the year? That's just three to five years. So it will be a, like, a mixed revenue because we we we work on a different verticals. So we have peptide, we have export, formulation, the metric. So if you see today's current revenue, almost 18% is export, 1820% is export, and that is API and formulation.

32:49 So in near future, you can see export going to around 30 to 35%, and that will be domestic and formulation. Okay. Okay. Thank Thank you for the opportunity. Thank you. Thank you. Thank you. The next question is from the line of from from iHeart Financial. Please proceed. Yeah. Thank you for the opportunity, sir. Sir, I wanted to ask about top three products that we have under each of the three segments that we report. API domestic, API exports and formulations.

33:35 And what would be their concentration in revenue mix? So for domestic, yeah, they're leading manufacturer, and it's all. So it is contributing to around nine to 10% or eight to 10%. In export, we have magnesium alternative and nutraceutical products, which is the biggest product right now. We are selling this to innovator in US. And formulation, it's a mixed product because it cannot be one product because we are doing a CDMO and assist business. Got it. And sir, this magnificent or Creonet business, could you quantify, like, how much did we do in FY twenty six, both in domestic and export market?

34:24 Sir, right now, we are doing only for the export market where we sell our logistical raw materials to the innovator. Last year, we did around... In quantities, we can say around three fifty metric ton. So how much would that be in value terms, if that is possible? 10% of total revenues. Got it. Got it. And, sir, our plan for this product for FY twenty seven? There's a growth of around 15 to 20%. Got it. Got it. And, if I recall, we were also trying to supply formulations to some other Indian players for magnesium and three unit. Any update on that project?

35:15 Yeah. We we already got an approval from The US counterpart, and we have approached almost six to seven companies in India. So hopefully, in next quarter, quarter three, we'll be launching at least two brands with two of the... Our senior partner. Got it. Got it, sir. And what kind of incremental revenues could we expect from this? This will be our first launch in a nutritional segment. So the... On... The revenue they have given is not... It's almost like one to 2% of total revenue. Got it. Got it, sir. And sir, on the semaglutide part, could you help us with the current API prices as of now?

36:03 Today, peptide on the semaglutide? Yes, sir. So today's market is anything between 120 to a $150 per gram. Got it, sir. Got it. And, sir, any volume expectations that we have for CEMA for next year? Not yet because our plan is similar transaction. It will be commercializing in quarter four of this year. Then only we can have the numbers. Got it. And sir, out of two fifty k g, how much have we allocated for semaglutide? It is not defined. The plan is is... The plan has been designed to manufacture altogether all the peptide, which has a different time cycles.

36:53 So it depends upon the which peptide has a margin and which which has a quantity. So it's not like defined Can we manage only 10 kgs or 20 kgs? It's not like that. It depends upon the requirement. Got it. Got it, sir. Got it. Sir, broadly, three, four years down the line, if you want to get to a top line of, let's say, thousand crores, and you have mentioned that peptide plan could easily do twin... 200 to $2.50 crores. So any sense on what would be the other key drivers that would generate the in... The rest of 100 and 150 crores? From our new development, which have the new product development, which we'll be doing next one to two years.

37:45 And the mid... Mixed product change from low value to high value. Got On the... These novel drugs that we have mentioned, like, we have got the approval and are on track for commercialization. Any expectations this year, revenue wise, that we have for this product? We only mentioned, yeah, right now, it is between 10 to 12 crores. Got it. And, sir, do we expect fewer exam to commercialize next year then? Next year, quarter four, because the patient is still there for. Got it. And, sir, any indications that you could give us about the market price for that product?

38:35 We we can send you offline that all the details. Sure. Sure. Sure. Understood. Got it, sir. Thank you so much. Thank you. Thank you. In the interest of the time, we take from SA Investment as the last question. You may proceed. Oh, thank you for the opportunity. Congratulations on first call. So I want to understand in terms of the long term potential of our revenues. So where do you think we can end up at? Because you mentioned the next year is gonna be ten percent, then we're gonna commercialize one of our plans in two years down the line. So I just wanted to understand Down the next two to three years, you can expect anything around 900 to thousand crore.

39:32 So time constraint, I would like to hand the conference over to you, Maheshal, for the closing comments. Thank you, everyone. Once again, I would like to say thank to our investors for having us on the call. Thank you. Thank you. On behalf of Bajaj Healthcare Limited, that concludes this conference. Thank you for joining us and you may now disconnect your lines.

Follow Bajaj Healthcare Ltd into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Ms. Bajaj

at MUFC Insight

Rohan Parekh

Chief Financial Officer at Bajaj Healthcare Limited

Anil Jain

at Bajaj Healthcare Limited

Nirali Shah

at Ashika Investment Management

More from Bajaj Healthcare Ltd